Αρχική World News Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive... World News Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer Από Ogkologos - 24 Νοεμβρίου, 2025 523 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests 9 Μαΐου, 2019 ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung... 23 Ιουνίου, 2020 ESMO–ESTRO Joint Consensus Papers Address the Safety of Combining Radiotherapy with... 5 Μαΐου, 2026 Cross-Border Network of European Specialists Provides New Treatment Options For Women... 17 Ιουνίου, 2024 Φόρτωση περισσοτέρων HOT NEWS The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That... FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage... FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020...